The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture ...
A research team co-led by scientists at the University of Arizona College of Medicine—Tucson found that an osteoporosis drug ...
The Osteoporosis Society of the Philippines Foundation Inc. (OSPFI) estimates that by 2050, around 10.2 million Filipinos ...
Skeletal conditions such as developmental dysplasia of the hip (DDH), osteoporosis, and osteoarthritis affect millions ...
The FDA has approved two new biosimilars of denosumab-dssb to treat osteoporosis, increase bone mass, prevent ...
A new case report was published in Oncoscience's Volume 12 on February 4, 2025, titled “Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.” ...
The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.
Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis ...
Celltrion’s two biosimilar treatments for treating osteoporosis and preventing bone metastasis complications in cancer ...
The Pelvic Obstetric and Gynaecological Physiotherapy (POGP) spoke to The Guardian about women’s weightlifting and ...
Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe ...